Albumin Excipient Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Human Serum Albumin, Recombinant Albumin), By End user (Pharmaceutical And Biotechnology Industry, Research Institutes, Others), By Region and Competition, 2020-2030F

November 2025 | 187 pages | ID: A1D68D9D0514EN
TechSci Research

Abstracts

The Global Albumin Excipient Market, valued at USD 4.98 Billion in 2024, is projected to experience a CAGR of 8.01% to reach USD 7.91 Billion by 2030. Albumin excipient is a highly purified protein, typically derived from human plasma or engineered recombinantly, utilized in pharmaceutical formulations as an inactive ingredient. Its primary functions include stabilizing active drug components, enhancing solubility, prolonging product shelf-life, and serving as a crucial element in cell culture media, vaccine production, and advanced drug delivery systems. The market's expansion is significantly driven by the escalating global demand for biopharmaceuticals and biologics, an increasing incidence of chronic diseases necessitating intravenous therapies, and continuous technological advancements in albumin production and purification processes.

Key Market Drivers

The global albumin excipient market is significantly propelled by the increasing demand for biopharmaceuticals and biologics, which rely heavily on albumin for stabilization and enhanced delivery. As the pharmaceutical industry increasingly focuses on complex protein-based therapies, albumin's unique properties as a non-immunogenic and effective stabilizer become indispensable. For example, according to the FDA's Center for Drug Evaluation and Research (CDER), in 2024, biologics accounted for 32% of all new drug approvals, a notable increase from the 28% average over the prior six years. This expanding pipeline and approval rate directly translate into a greater need for high-quality albumin excipients to ensure the safety, efficacy, and shelf-life of these advanced therapeutic products.

Key Market Challenges

The challenging factor for the Global Albumin Excipient Market is the inherently high production costs associated with both plasma-derived and recombinant albumin manufacturing. This significant impediment stems from the complex and resource-intensive processes required for both sources. For plasma-derived albumin, extensive collection networks, rigorous purification, and stringent safety testing contribute substantially to expenses. Similarly, recombinant albumin manufacturing necessitates sophisticated biotechnological processes, specialized equipment, and considerable research and development investments. These factors collectively drive up the cost of the final excipient.

Key Market Trends

The increasing adoption of recombinant albumin excipients addresses critical supply and safety considerations. Unlike plasma-derived albumin, recombinant alternatives offer enhanced consistency, a reduced risk of viral contamination, and overcome the ethical and supply chain challenges associated with human plasma sourcing. This shift is becoming increasingly necessary; according to the International Plasma and Fractionation Association (IPFA) and European Blood Alliance (EBA) symposium proceedings in August 2025, the European Medicines Agency anticipated plasma shortages to affect 14 European countries in 2024, highlighting the persistent supply challenges for plasma-derived products.

Key Market Players

• Albumin Therapeutics LLC
• Biotest AG
• CSL Limited
• HiMedia Laboratories
• Medxbio Pte Ltd.
• Octapharma AG
• RayBiotech Inc
• SeraCare (LGC Clinical Diagnostics, Inc.)
• Sigma-Aldrich (Merck KGaA)
• LFB USA , Inc.

Report Scope:

In this report, the Global Albumin Excipient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Albumin Excipient Market, By Product:
• Human Serum Albumin
• Recombinant Albumin
• Albumin Excipient Market, By End user:
• Pharmaceutical and Biotechnology Industry
• Research Institutes
• Others
• Albumin Excipient Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Albumin Excipient Market.

Available Customizations:

Global Albumin Excipient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ALBUMIN EXCIPIENT MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Product (Human Serum Albumin, Recombinant Albumin)
  5.2.2. By End user (Pharmaceutical and Biotechnology Industry, Research Institutes, Others)
  5.2.3. By Region
  5.2.4. By Company (2024)
5.3. Market Map

6. NORTH AMERICA ALBUMIN EXCIPIENT MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product
  6.2.2. By End user
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Albumin Excipient Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Product
      6.3.1.2.2. By End user
  6.3.2. Canada Albumin Excipient Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Product
      6.3.2.2.2. By End user
  6.3.3. Mexico Albumin Excipient Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Product
      6.3.3.2.2. By End user

7. EUROPE ALBUMIN EXCIPIENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product
  7.2.2. By End user
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Albumin Excipient Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product
      7.3.1.2.2. By End user
  7.3.2. France Albumin Excipient Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product
      7.3.2.2.2. By End user
  7.3.3. United Kingdom Albumin Excipient Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product
      7.3.3.2.2. By End user
  7.3.4. Italy Albumin Excipient Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product
      7.3.4.2.2. By End user
  7.3.5. Spain Albumin Excipient Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product
      7.3.5.2.2. By End user

8. ASIA PACIFIC ALBUMIN EXCIPIENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product
  8.2.2. By End user
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Albumin Excipient Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product
      8.3.1.2.2. By End user
  8.3.2. India Albumin Excipient Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product
      8.3.2.2.2. By End user
  8.3.3. Japan Albumin Excipient Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product
      8.3.3.2.2. By End user
  8.3.4. South Korea Albumin Excipient Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product
      8.3.4.2.2. By End user
  8.3.5. Australia Albumin Excipient Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product
      8.3.5.2.2. By End user

9. MIDDLE EAST & AFRICA ALBUMIN EXCIPIENT MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product
  9.2.2. By End user
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Albumin Excipient Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product
      9.3.1.2.2. By End user
  9.3.2. UAE Albumin Excipient Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product
      9.3.2.2.2. By End user
  9.3.3. South Africa Albumin Excipient Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product
      9.3.3.2.2. By End user

10. SOUTH AMERICA ALBUMIN EXCIPIENT MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product
  10.2.2. By End user
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Albumin Excipient Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product
      10.3.1.2.2. By End user
  10.3.2. Colombia Albumin Excipient Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product
      10.3.2.2.2. By End user
  10.3.3. Argentina Albumin Excipient Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product
      10.3.3.2.2. By End user

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL ALBUMIN EXCIPIENT MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Albumin Therapeutics LLC
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Biotest AG
15.3. CSL Limited
15.4. HiMedia Laboratories
15.5. Medxbio Pte Ltd.
15.6. Octapharma AG
15.7. RayBiotech Inc
15.8. SeraCare (LGC Clinical Diagnostics, Inc.)
15.9. Sigma-Aldrich (Merck KGaA)
15.10. LFB USA , Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER